# Adipotide (FTPP)

> Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide), is an experimental compound studied in animal models for its ability to induce localized apoptosis (programmed cell death) in the blood vessels supplying white adipose tissue. Studies in obese primates reported rapid and substantial fat-mass reduction, but also raised safety concerns, including effects on kidney function. It has not been tested in human clinical trials for safety or efficacy, and it is not an approved or clinically validated weight-management therapy. Given its mechanism and unresolved safety signals, it is regarded as a high-risk research compound rather than a viable weight-loss option.

- URL: https://www.lifeconverted.com/peptides/adipotide
- Also known as: FTPP, Fat-Targeted Proapoptotic Peptide
- Primary category: Weight Management
- Effectiveness rank: #10 in Weight Management
- Evidence level: Emerging research
- Route: Subcutaneous (Human clinical dosing has not been established; available data are derived from animal studies only.)
- Dose range: 0.5-2 mg
- Dose tiers: low 0.5 mg; moderate 1 mg; high 2 mg
- Half-life: Not established in humans; limited preclinical pharmacokinetic data are available
- Timing: Morning
- Cycle: No established human protocol on, No established human protocol off (All available protocol information derives from primate research and has not been validated for human use.)
- Storage: Store as a research compound per supplier instructions, typically frozen or refrigerated and protected from light; not manufactured or labeled as a human pharmaceutical.

## Mechanism of action

Adipotide is a peptide conjugate that binds to a receptor (prohibitin) found on the blood vessels feeding white adipose tissue and delivers a pro-apoptotic signal, causing programmed cell death of those vessels. Disrupting blood supply to fat tissue is proposed to cause rapid fat-cell death and tissue mass reduction, a mechanism distinct from appetite suppression or metabolic rate changes seen with other weight-related compounds, based on animal research.

## Reported benefits

- Rapid, substantial fat-mass reduction reported in primate studies
- Mechanism distinct from appetite- or incretin-based weight agents
- Has generated research interest in vascular-targeted approaches to fat reduction

## Reported side effects

- Kidney function changes observed in primate studies
- No established human safety data
- Mechanism (inducing localized cell death) carries theoretical risk of unintended tissue damage
- Not evaluated for long-term safety in any species

## Common protocols

- No standardized human protocol exists; documented use is confined to primate research studies

## Stacking notes

Not established; no controlled data exist on combination with other weight-related compounds, and doing so is not supported by any published research.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer